Clinical Laboratory Analysis
Started, developed and operated multiple high complexity clinical laboratories for over 10 years with emphasis in general chemistry, hematology, immunoassay, infectious disease, hormones and anti-aging and toxicology utilizing sophisticated resources such as LCMS and PCR.
Clinical Laboratory Analysis Posts
FDA’s Shift on Testosterone: A Long-Awaited Reversal
The U.S. Food and Drug Administration (FDA) has once again reversed course on a major drug safety issue—this time, on testosterone therapy. In response to findings from the TRAVERSE clinical trial and post market ambulatory blood pressure (ABPM) studies, the FDA is...
Third Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications
The much anticipated announcement of the Third Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications effective 15 November 2024. When Covid began the DEA needed to find a solution to allow patients access to care...
Novo Nordisk asks the FDA to add Semaglutide to the Demonstrably Difficult to Compound list.
On October 22, 2024, Novo Nordisk asked the FDA to add semaglutide to the demonstrably difficult to compound list. The Food and Drug Administration is proposing to establish criteria for the lists of drug products or categories of drug products that present...
FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of some of these peptides.
The FDA stirred enormous controversy when, without much notice, they placed some of the most popular peptides on their category 2 list, which disallows the compounding with these bulk substances also known as (APIs) Active Pharmaceutical Ingredients. Many of the...
Tirzepatide may not be removed from the FDA drug shortage list after all.
This week the pharmacy compounding, weight loss and anti-aging communities have been abuzz from the October 2, 2024 announcement from the FDA and Eli Lilly that they are removing both of the brand name tirzepatide blockbuster drugs, Mounjaro® and Zepbound® from the...
Anderson Triggs
Curriculum Vitae The Professional Resume of Anderson Triggs The Education of Anderson L Triggs Masters in Business Administration, with Honors, May 2010, Nova Southeastern University, Davie, FL. Elected to Sigma Beta Delta Business Honorary Bachelor in Business...